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ABSTRACT
Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added
cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are
needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent
currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the
treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line
(n 24) or first-line (n 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%)
of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15
(44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30
patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-
100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three
patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These
data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial
effect on the survival of patients with this complication.
© 2005 American Society for Blood and Marrow Transplantation
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Mycophenolate mofetil (MMF) is an antimetabo-
ite that results in noncompetitive, reversible inhibi-
ion of inosine monophosphate dehydrogenase. This
eads to selective inhibition of lymphocyte purine syn-
hesis and proliferation [1]. It has been successfully
sed for the prevention of acute rejection in renal
llograft recipients [2]. MMF was initially tested for
one marrow transplantation in experimental animal
odels of matched and mismatched transplants that
howed superiority of cyclosporine (CSA)/MMF over
SA/methotrexate (MTX) in acute graft-versus-host
isease (aGVHD) prophylaxis [3]. It has subsequently
een extensively used with success in patients as f
B&MTGVHD prophylaxis after nonmyeloablative bone mar-
ow transplantation [4]. It has also been used in limited
rials for the treatment of aGVHD and chronic graft-
ersus-host disease (cGVHD) [1,5-12]. These reports
ave suggested that MMF is an active agent in these
ettings. The toxicity proﬁle of MMF (upper and lower
nteritis and cytopenia, with a lack of renal toxicity) is
ot cross-reactive with that of prednisone (PSE) and
SA or tacrolimus (FK506), the drugs currently used in
tandard ﬁrst-line therapy for cGVHD, and this makes it
ttractive as a candidate for combination therapy. Cur-
ent treatment of cGVHD with PSE alone or with
dded CSA/FK506 still has a high mortality and com-
lication rate, and new treatment approaches are needed
or both primary and salvage therapy [13-16].
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3In 1999 we began to test the effectiveness of MMF
n the treatment of cGVHD when added to either
tandard ﬁrst-line or second-line/salvage therapy. We
ave now conducted a retrospective analysis of 34
atients treated with this approach at our institution
nd have evaluated the cGVHD clinical response rate,
he ability to taper steroids in, and the overall survival
f this group.
ATIENTS AND METHODS
This retrospective review was approved by the Insti-
utional Review Board of the City of Hope National
edical Center. The review included all patients at our
nstitution who ﬁlled prescriptions for MMF for treat-
ent of cGVHD between March 1999 and January
001. Although this was not a prospective study, all
atients who were identiﬁed as having started MMF
reatment for cGVHD during the review period were
ncluded without selection. There were no competing
GVHD treatment protocols at the time to drive selec-
ion of patients. This group represented patients for
hom the physician believed that additional ﬁrst-line or
ew second-line treatment was necessary in addition to
tandard PSE and or CSA/FK506. A total of 34 patients
ere identiﬁed who were treated with MMF for
GVHD. Ten patients received MMF as part of ﬁrst-
ine therapy upon the initial diagnosis of cGVHD. Eight
f these 10 ﬁrst-line patients had a history of aGVHD
nd were already undergoing a PSE taper at the time
f ﬁrst diagnosis of cGVHD. Of these, 6 had quiescent
GVHD (resolved aGVHD-free interval before
GVHD), and 2 had progressive cGVHD (unresolved
GVHD that progressed to cGVHD). Their physi-
ians therefore started MMF at the diagnosis of
GVHD because it developed while the patient was
lready taking PSE. Two other ﬁrst-line patients were
ot taking PSE at the time of ﬁrst diagnosis of
GVHD; 1 had increased creatinine, limiting CSA
se, and the other had no limitation to standard treat-
ent, but his physicians wanted to avoid steroid ex-
osure in a pediatric patient.
Twenty-four patients received MMF as salvage
herapy because of persisting or worsening cGVHD
espite the ﬁrst-line treatment. In 2 of these patients,
here was also a greater urgency to taper or withhold
SE because of diabetes (n  1) and avascular hip
ecrosis (n  1) and to taper or withhold CSA in 3
atients because of CSA related neurotoxicity (n  1),
ncreased creatinine (n  1), and hemolytic uremic
yndrome (n  1).
The median age was 32 years (range, 2.5-55 years).
he patients had undergone matched sibling (n 17),
elated (n  2), or unrelated (n  15) non–T cell–
epleted allogeneic transplantations. The aGVHD
rophylaxis regimens used were CSA, MTX, and PSE r
08n  18); CSA/MTX (n  10); CSA/MMF (n  2);
nd others (n  4). The source of stem cells was bone
arrow (n  29), peripheral blood (n  4), or cord
lood (n  1). The characteristics of the 34 patients
ith cGVHD at initiation of MMF therapy are listed
n Table 1.
All patients initiated treatment with MMF no
arlier than day 80 after transplantation and con-
inued prior therapy with PSE, CSA, or FK506
hen MMF was started. MMF was started in most
dult patients at 500 mg twice daily (BID) and then
scalated if tolerated to 1000 mg BID. Data re-
orded at the initiation of MMF and at a minimum
ollow-up of 6 months included the date of diagno-
is of cGVHD and the starting date of treatment
ith MMF; the type of onset of cGVHD (progres-
ive, de novo, or quiescent); and the sites of
GVHD-related organ involvement. Clinical organ
nvolvement (skin, mouth, and eyes) was also de-
cribed as mild, moderate, or severe by the primary
hysician. In addition, the extent of skin involvement,
latelet count, and liver function tests were quantiﬁed.
he immunosuppressive therapy previously used for the
revention and treatment of GVHD, the current im-
unosuppressive medications, and PSE doses at the
tart of MMF therapy and at last follow-up were
ecorded. Clinical responses were classiﬁed as com-
lete remission (CR), complete resolution of all man-
festations; partial remission (PR), partial response re-
uiring improvement in liver function tests or
mprovement of the clinical manifestations from se-
ere to moderate to mild; stable disease, no change;
nd PD, progressive disease. We also calculated the
ercentage change in PSE doses at the end of the
-month observation period as an additional measure
f the quality of the response.
There was no structured sequence or rate of
rug tapering according to response, but the stan-
ard approach was to taper steroids ﬁrst. MMF
osage was also adjusted on the basis of toxicity
cytopenia, gastrointestinal discomfort, or infec-
ions) and response. At the time of last follow-up
minimum of 6 months), the status of cGVHD re-
ponse, PSE dosage, additional GVHD treatment in
se, remission, survival, and intervening complica-
ions were evaluated.
Standard institutional supportive care for patients
ith cGVHD was continued. This included monitor-
ng for cytomegalovirus (CMV) viremia with blood
ultures for immediate early antigen in those with a
istory of CMV infection or in patients within 6
onths of bone marrow transplantation who required
ncreasing doses of PSE. Itraconazole and acyclovir
rophylaxis were also routinely used for patients who
equired increasing doses of PSE.
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MMF in Treatment of cGVHD
BESULTS
esponse and Survival
Response, complication, and survival data are listed
n Tables 2 and 3. The median follow-up time for all
atients from initiation of MMF therapy was 24
onths (range, 6-28 months). The median time for a
atient to show initial signs of a response was 17 days
range, 7-58 days). This was calculated as the time to
he ﬁrst objective signs of any improvement, not as the
ime to maximum response. In patients receiving
MF as part of initial therapy for cGVHD, 9 of 10
atients responded (CR, n  7; PR, n  2; stable
isease, n  1). In those receiving MMF as second-
ine treatment, 18 of 24 patients responded (CR, n 
; PR, n  13; stable disease, n  4; PD, n  2). The
esponses by organ site involved are listed in Table 3.
Four of the 34 patients were not receiving PSE at
he time MMF was started (ﬁrst line, n  2; second
ine, n  2). In this group, responses included 1 CR,
PR, and 1 stable disease. Of the 30 patients taking
SE at the time MMF was started, 22 (73%) had a
ecrease in PSE dose (median decrease, 50%; range,
able 1. Pretreatment Characteristics of cGVHD
Variable Firs
e novo
uiescent
rogressive
latelet count
<100 000/L
>100 000/L
kin involvement
None
<50% body-surface area
>50% body-surface area
linical classification of cGVHD
Limited
Extensive
Mild
Moderate
Severe
PS
edian time to diagnosis of cGVHD from BMT
ime to start MMF from diagnosis of cGVHD
t time of diagnosis (first line)
<1 y
>1 y
mmunosuppressive therapy before MMF
CSA/PSE
FK506/PSE
CSA or FK506/PSE/photopheresis
PSE
CSA
FK506
CSA/PSE/thalidomide
CSA/PSE/PUVA
CSA/PUVA
edian age, 32 years; range, 2.5 to 55 years.
PS indicates Karnofsky performance status; BMT, bone marrow5%-100%) by the end of the minimum 6-month a
B&MTbservation period (but only 1 patient was successfully
apered off), with 11 CR, 10 PR, and 1 stable disease.
he median PSE dose at the start of MMF treatment
as 10 mg and did not change over the 6-month
bservation period, but the range improved from
-120 mg/d to 0-40 mg/d.
Three patients were unable to taper PSE after
tarting MMF and remained with no change in dose (2
R and 1 stable disease). Five patients had to increase
heir PSE doses after starting MMF (median, 50%;
ange, 25%-60%), with 0 CR, 1 PR, 2 stable disease,
nd 2 PD. Twenty-nine (85%) of 34 patients are alive,
ncluding 9 (90%) of 10 in the ﬁrst-line treatment
roup and 20 (83%) of 24 in the salvage group.
hrombocytopenia at diagnosis of cGVHD and pro-
ressive onset from acute to chronic phase are 2 well-
stablished prognostic factors for poor outcome with
GVHD [17,18]. In this MMF-treated group, 14
87%) of 16 patients with thrombocytopenia or pro-
ressive-onset cGVHD survived. Overall, 21 (61%) of
4 patients had a favorable outcome (CR or PR, with
SE dose decreased when taking this medication, and
reatment
TotalSalvage
12 14
3 9
9 11
4 8
20 26
10 12
8 13
7 10
1 2
23 32
13
10
1
Median, 80%; range, 60%-100%
112 d (range, 80 d to 17 mo)
11
13
10 16
6 9
3 3
1 2
0 2
1 1
1 1
1 1
1 1
antation; PUVA, psoralen and UV-A.T
t Line
2
6
2
4
6
2
5
3
1
9
6
4
10
5
2
0
1
2
0
0
0
0live) after the institution of MMF.
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3MF Dosing
In the 28 adult patients, 1 started MMF at 250 mg
ID, 21 at 500 mg BID, 1 at 750 mg BID, and 5 at
000 mg BID. At 1 month after therapy, 2 were
eceiving 250 mg BID, 5 were receiving 500 mg BID,
nd 20 were receiving 1000 mg BID. At 6 months
fter therapy, 1 was receiving 250 mg every other day,
were receiving 250 mg BID, 9 were receiving
00 mg BID, 11 were receiving 1000 mg BID, and 1
as receiving 1000 mg 3 times daily.
oxicity and Complications
Three patients had to discontinue MMF because
f abdominal cramps. One patient developed neutro-
enia that was attributed to the drug but required only
ose adjustment. There were 12 infectious episodes
uring treatment (CMV viremia, n  2; CMV pneu-
onia, n 2; inﬂuenza A, n 3; herpes simplex virus,
able 2. Results
Variable
Treatment
TotalFirst Line Salvage
esponse
Complete 7 5 12 (35%)
Partial 2 13 15 (42%)
Stable 1 4 5 (14%)
Progression 0 2 2 (5%)
teroid-sparing effect 8 22 30
Decrease (median, 50%;
range, 25%-100%) 8 14 22
No change in dose 3 3
Increase (median, 50%;
range, 25%-60%) 5 5
isease status at last
follow-up
Remission 33
Relapse 1
omplications
Abdominal cramps 3
Neutropenia 1
Infection
CMV viremia 2
Influenza type A 2
Sepsis, CMV
pneumonia 1
Influenza A, CMV
pneumonia,
aspergillus 1
Interstitial
pneumonia 1
HSV 3
Warts 1
urvival
Alive 9 20 29(85%)
Dead 1 4 5(15%)
Progression cGVHD 1 1
Relapse 1 1
Infection 1 2 3
edian time to initial response was 17 days (range, 7-58 days).
SV indicates herpes simplex virus. 3; warts, n  1; and aspergillosis, n  1). Five G
10atients died after starting MMF treatment: relapse
n  1), refractory liver GVHD (n  1), and infection
n  3; aspergillus, n  1; inﬂuenza A, n  1; and
MV pneumonia, n  1).
ISCUSSION
Chronic GVHD is a syndrome with a large range
f disease manifestations. Prognosis in these patients
s affected not only by the severity and site of organ
nvolvement, but also by many other associated fac-
ors, such as the time of onset after transplantation,
rior resolution of aGVHD, age, comorbidity, the
isease for which the transplantation was performed,
he type of transplantation (unrelated or matched sib-
ing donor), and, possibly, the source of stem cells
peripheral blood or bone marrow) [19]. This has
omplicated the development of a reproducible stag-
ng and prognostic system that can be used to compare
atient populations and outcomes in different treat-
ent trial results for cGVHD, such as our current
ne. The Seattle Group [20] originally developed the
imited/Extensive staging system in 1980, but the
xtensive group includes a variety of patients with
iffering prognoses. They then reported that associ-
ted thrombocytopenia and progressive onset were
oth associated with a high risk for complications and
oor outcome, thus helping to further deﬁne cGVHD
rognostic groups [14]. Recently, progress has been
ade in developing new prognostic models that, when
pplied to varied population groups with cGVHD,
ave been able to subdivide them into standard-, low-,
ntermediate-, and high-risk groups in terms of treat-
ent-related mortality and survival [19]. These in-
lude the Hopkins model reported by Akpek et al. [17]
nd the International Bone Marrow Transplant Reg-
stry staging system reported by Lee et al. [21] Studies
re ongoing to validate these differing currently avail-
ble staging systems and to consolidate them into 1
able 3. Response According to cGVHD Organ Involvement
First-Line and Second-Line Patients)
Organ
Response (n  34) Stable
Disease
(n  5)
PD
(n  2)
CR
(n  12)
PR
(n  15)
kin only 4 3 2
kin/GI 2 1
kin/mouth 1 4 1
kin/mouth/eye 1 1
kin/liver 1 2 1
kin/mouth/liver 1
iver only 1 1
iver/mouth 2 1
outh only 1
outh/esophagus 1
I 2I indicates gastrointestinal.
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Bcale that can be generally applied to cGVHD patient
opulations. We would then be able to compare differ-
nt treatment approach results in prognostically similar
roups of patients and deﬁne which patients need addi-
ional approaches to standard therapy. The main risk
actors identiﬁed in the recent Akpek/Hopkins and In-
ernational Bone Marrow Transplant Registry staging
ystems as signiﬁcant in addition to thrombocytopenia
nd progressive onset are extensive skin involvement
ESI), liver involvement, Karnofsky performance sta-
us, and gastrointestinal involvement.
Response and survival in our MMF-treated group
ere improved compared with a prior phase II trial of
halidomide for salvage or second-line treatment of
GVHD at our center (1987-1994; 86 patients; 38 at
igh risk with thrombocytopenia, progressive cGVHD,
r combined skin/liver involvement; median follow-up,
.6 years), where we observed a 20% overall response
ate (16% in the high-risk group), with a 36% discon-
inuation of drug because of side effects and a 53%
verall survival rate [22]. Flowers [18] reviewed the re-
ults of ﬁrst-line treatment with CSA/PSE for their
igh-risk cGVHD group, deﬁned as those with progres-
ive onset or thrombocytopenia (platelets 100 000/
L). Survival was 48% at 3 years and 39% at 10 years
1985-1989; 111 patients; 10.8-year median follow-up).
n our MMF-treated group (combined ﬁrst-line and
alvage), 14 (87%) of 16 patients with thrombocytopenia
100 000/L) or progressive onset are alive at a median
-year follow-up.
Akpek et al. [17] reviewed the outcome for 151
atients with cGVHD at their center treated on se-
uential protocols between 1979 and 1998. With a
.8-year median follow-up, overall survival was 51%.
hey then looked at outcome according to the prog-
ostic factor scale (PFS) they developed. This system
ses 3 cGVHD-related manifestations to produce an
verall score that they found to be prognostically
igniﬁcant for survival. The variables used to score
nclude ESI, thrombocytopenia (TP; 100 000/L),
nd progressive-type onset (PTO). A PFS of 0 has
one of these factors, and a PFS 2 has single ESI,
P, or PTO or TP and PTO combined. A PFS of 2
o 3.5 has ESI plus either TP or PTO, and a PFS3.5
as all 3 variables. Survival for their patients (with
FS assigned at diagnosis of cGVHD) was 82% for
FS 0, 68% for PFS 2, and 34% for PFS 2 to 3.5.
urvival analysis for our patients subdivided by PFS
as 80% for PFS 0, 87% for PFS 2, and 100% for
FS 2 to 3.5.
In a more recent update from Koc et al. [16] on
ong-term results with a randomized trial of CSA/PSE
ersus PSE (1985-1992) for cGVHD, the 45 patients
ith high-risk disease deﬁned by progressive onset
ad a 5-year survival of 43% on CSA/PSE versus 76%
n PSE. The authors pointed out that adding CSA to
SE did not improve results and that new approaches t
B&MTere needed, especially for high-risk cGVHD. Our
esults are in a smaller group of patients with a shorter
ollow-up, are more contemporary, and beneﬁted
rom improved supportive care in relation to the pre-
iously cited results of Akpek, Flowers, and Koc and
ur own thalidomide-treated group and therefore are
ot directly comparable. Nevertheless, the addition of
MF seemed to have activity, especially as measured
y the decrease in PSE requirements and the possible
mproved outcome for the higher-risk patients with
hrombocytopenia and progressive onset. Our patient
opulation had 16 (47%) of 34 high-risk patients clas-
iﬁed by thrombocytopenia or progressive onset, com-
ared with 111 (47%) of 237 in the group reported by
lowers and 38 (44%) of 86 in our prior thalidomide
rial. However, compared with the group reported by
kpek, we had more patients with lower PFS scores
63% [City of Hope] versus 55% [Hopkins] with PFS
2 or 0) in our cGVHD population.
The median time for a patient to show initial signs
f a response to MMF was 17 days (range, 7-58 days).
his was the time to the start of any improvement and
ot the time to maximum response. We recommend,
herefore, that when MMF is given for treatment that
t be continued for at least 2 months before treatment
ailure is declared.
Only 3 patients (11%) had to discontinue MMF
ecause of side effects (all because of abdominal cramps).
MF was otherwise well tolerated. Eleven of 34 pa-
ients developed infectious complications, but only 3
ied directly as a result of infection. There did not
eem to be an increased incidence of relapse in our
tudy population despite the use of increased immu-
osuppression with MMF.
In addition to looking at response, survival, and
oxicity in this review of our GVHD treatment results
ith MMF, we also incorporated an additional analysis
f the PSE dose a patient required at the timeMMFwas
tarted and the effect of MMF treatment on PSE doses.
atients taking long-term steroids develop signiﬁcant
orbidity and are at risk of mortality from infections.
MF has non–cross-reactive toxicities with CSA/
K506/PSE and therefore allows additional therapy
ithout increasing existing drug-speciﬁc toxicity.
ore importantly, if effective, it may allow a signiﬁ-
ant steroid-sparing effect. Roberts et al. [11] reported
decrease in PSE dose in 73% of the patients with
teroid-resistant cGVHD of the liver with MMF. We
lso conﬁrmed this steroid-sparing effect in our
MF-treated group. However, although 73% of our
atients were also able to decrease PSE doses when
MF was added, only 1 patient was able to be
apered off. This speaks to the fact that MMF
eemed to be a useful adjunctive therapy to standard
SE/CSA/FK506 for cGVHD treatment in our pa-
ients but did not lead to a complete resolution of
he problem in most patients. Nevertheless, the
311
s
i
w
f
w
h
a
a
f
s
1
l
r
w
W
t
w
W
1
s
w
2
i
i
f
d
t
t
t
s
w
o
o
ﬁ
r
s
T
p
t
s
t
r
p
p
A
S
R
1
1
1
1
1
1
1
1
1
1
2
F. Lopez et al.
3teroid-sparing effect may be important for reduc-
ng both morbidity and mortality in these patients,
ho often need to remain on treatment for cGVHD
or months or years. The small group of 5 patients
ho had to increase the PSE dose and remain on
igher PSE doses after being started on MMF had
poor outcome: 0 CR, 1 PR, 2 stable disease, 2 PD,
nd 2 deaths in the 5 patients.
This retrospective review analyzed outcome only
or patients started on MMF for cGVHD at our in-
titution over the 22-month review period (March
999 to January 2001) with a subsequent median fol-
ow-up of 24 months. We did not conduct a parallel
eview of all other patients treated for cGVHD who
ere not receiving MMF during the review period.
e therefore do not have a contemporary population
o compare or a direct analysis of why other patients
ith cGVHD were not placed on MMF at the time.
e did participate in a phase III trial between March
996 and July 1999 of bone marrow or peripheral
tem cell allogeneic sibling transplantation for patients
ith hematologic malignancies [23]. We contributed
0 of the total 172 patients entered on the study by 3
nstitutions. This study was subsequently reviewed for
ncidence and outcome of cGVHD, with a median
ollow-up of 40 months [24]. Seventy-one patients
eveloped extensive cGVHD. Only 4 of these were
reated with MMF as part of ﬁrst-line therapy for
heir cGVHD. Twenty (28%) responded to ﬁrst-line
reatment, and the others required additional succes-
ive treatments to control cGVHD. Overall survival
as 59 (83%) of 71. Although survival was similar
verall in our MMF treatment review group (86%), 9
f 10 patients who were placed on MMF as part of
rst-line therapy for cGVHD responded and did not
equire secondary therapy.
MMF is a drug well suited for inclusion into a
tudy of ﬁrst-line or high-risk cGVHD therapy.
his is an issue that will be further addressed in
rospective trials. We conclude that MMF has ac-
ivity in the treatment of cGVHD, has a steroid-
paring effect, and does not seem to increase infec-
ious complications or disease relapse. MMF may
educe morbidity and improve survival of cGVHD
atients even in those currently deﬁned as having
oor-risk factors.
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